Breaking Finance News

Quintiles IMS Holdings Inc (NYSE:Q) target price raised to $93.00, reported today by Robert W. Baird

Just yesterday Quintiles IMS Holdings Inc (NYSE:Q) traded 1.53% higher at $87.86. Quintiles IMS Holdings Inc’s 50-day moving average is $90.01 and its 200-day moving average is $83.51. The last stock price is up 6.47% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.05% over the same time period. 1,006,508 shares of Q traded hands, up from an average trading volume of 992,995

Quintiles IMS Holdings Inc (NYSE:Q) had its stock price target increased to $93.00 by Robert W. Baird in an issued report issued Friday July 07, 2017. The upped stock price target indicates a possible upside of 0.06% based on the company's previous stock price.

Previously on Thursday June 29, 2017, Citigroup released a statement about Quintiles IMS Holdings Inc (NYSE:Q) reduced the target price from $97.00 to $96.00. At the time, this indicated a possible upside of 0.07%.

Recent Performance Chart

Quintiles IMS Holdings Inc (NYSE:Q)

Quintiles IMS Holdings Inc has 52 week low of $70.10 and a 52 week high of $93.53 with a PE ratio of 257.71 and has a market capitalization of $0.

In addition to Robert W. Baird reporting its target price, a total of 15 firms have reported on the stock. The consensus target price is $76.50 with 8 firms rating the stock a strong buy, 9 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Quintiles IMS Holdings Inc (NYSE:Q)

Quintiles IMS Holdings, Inc., formerly Quintiles Transnational Holdings Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.